It was natural that anabolic steroids should be tried in combination with corticosteroids in the treatment of rheumatoid arthritis in an attempt to prevent or reverse steroid osteoporosis. Several reports (Spilborghs 1962 , Caruso et al. 1962 , Clark & Mills 1962 , Katona et al. 1963 ) have now appeared which claim a synergistic effect between the two, enabling the dose of corticosteroid to be reduced without change in the clinical state. It is with this aspect that we wish to deal.
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The only report in English literature is that by Clark & Mills (1962) . They treated two groups of patients. The first group of 12 patients they described as steroid intoxicated. Eleven of these were admitted to hospital. They were given 15 mg methandrostenolone daily and the average daily dose of prednisone was reduced from 15 2 mg to 4*2 mg over six weeks. Bed rest may have played some part in this, and so they treated a second group of 12 outpatients in an open trial, giving 10 mg methandrostenolone daily for six weeks.
The average dose of prednisone fell from 8&5 mg to 6 mg daily and the Lansbury systemic index from 78 to 48 (Lansbury 1958) . On discontinuation of the anabolic steroid the index rose to 68 on the same corticosteroid dose. On restarting anabolic steroid, however, the index fell only to 60. Katona et al. (1963) have reported their work on the combination of paramethasone and oxymetholone in the therapy of rheumatoid arthritis. It was suggested that the dose of paramethasone can be reduced and with it the side-effects of longterm steroid therapy; a dose reduction of 40-4 % was achieved in the group treated with oxymetholone compared with the controls. Their paper appeared after the trial which is the subject of our report but prompted us to think that it might be worth while to give the results of a doubleblind trial in which a cross-over pattern was employed and which extended over a longer period.
Material and Methods
Patients were selected for this trial who had been on a stable dose of corticosteroid for at least six months prior to entry. Two initial assessments were made at monthly intervals before starting treatment with anabolic steroid and one assessment was made a month after completion of the trial. The patients were observed at intervals of one month during the trial. Three months were allowed for placebo treatment and three months for active treatment. It was hoped that by using a long period of observation the effect of spontaneous remission and relapse would be diminished.
The anabolic steroid selected was oxymetholone in a dosage of 7-5 mg per day. This dose was chosen as the result of previous studies by Gomez-Mont & Lasso (1960) and Myerson (1961) to determine the optimum anabolic dosage.
Sixteen patients entered the trial. One had polymyositis and was included as a matter of interest but was not assessable. One patient, who had received placebo only, developed jaundice and was withdrawn from the trial; another, aged 81, also on placebo, died from bronchopneumonia during the second month of the trial.
Of the 13 patients who completed the period of observation 9 were women and 4 men, of average age 57-7 years (range 45-75 years) and the average duration of rheumatoid arthritis before entry into the trial was six and a half years (range two to fifteen years). Steroid therapy had been administered for an average period of 23 4 months (range six months to five years). These were assessed on the Lansbury articular and systemic indices (Lansbury 1958) , this being the method used in the previously mentioned reports.
If the group of patients who received placebo first is compared with those who received the active drug first, neither shows a significant change according to Lansbury's criteria. This is confirmed by the graph (Fig 1) showing mean values for articular and systemic indices together.
Further examination of individual items recorded showed that average grip for all placebo observations and active observations was identical at 149 mmHg. Only the ESR showed a definite difference. The average for the placebo-treated group was 27 mm in the first hour (Westergren), whereas for the active group the figure was 23 mm in the first hour.
Side-effects Estimations of haemoglobin, white cell count and liver function tests were carried out monthly but no significant changes were detected. Increased mooning and acne were noted in only two patients while on active drug.
Discussion
In this trial it has not been possible to demonstrate more than a slight cortisone-sparing effect from the addition of an anabolic steroid. Reduction in steroid dosage by 20-25% was obtained for 3 cases (23 %) during active treatment and for one case during placebo therapy.
Thus the drug did not allow reduction in 10 cases (77 %) and gave rise to an average increase of the systemic and articular indices of 17 in those patients who had their cortisone reduced. This rise is over 15, so Lansbury would consider it as significant.
One patient, however, showed definite benefit and her articular index fell by 45 whilst on active drug. It may be of significance, in view of its known myopathic tendency, that this patient was taking triamcinolone.
The patients in the trial were chosen because of the stability of their disease and this has meant that the Lansbury index has been considerably lower than that in the trials of Clark & Mills (1962) and of Katona et al. (1963) . A marked synergistic effect should, however, have been revealed in a lowering of the index even when steroid dosage could not be reduced. Lack of this effect is further suggested by the rise in the index in those patients in whom steroid dosage was reduced.
